Expanded Programme on Immunization, World Health Organization, Geneva, Switzerland.
J Infect Dis. 2020 Sep 1;222(7):1117-1128. doi: 10.1093/infdis/jiaa044.
Measles incidence and mortality rates have significantly decreased since vaccine introduction. Despite this progress, however, there has been a global resurgence of measles. To understand the current global epidemiology, we analyzed measles surveillance data.
We analyzed data on measles cases from 2013-2018 reported to the World Health Organization. Univariate analysis was undertaken based on age, vaccination history, onset year, World Health Organization region, and World Bank income status for the country where the case was reported, and a surrogate indicator of the historical strength of the country's immunization program. Annual incidence and a 2013-2018 mean country incidence per million were calculated.
From 2013 through 2018, there were 899 800 reported measles cases, of which 57% occurred unvaccinated or undervaccinated persons, with an unknown vaccination history in another 30%. Lower-middle-income countries accounted for 66% of cases, 23% occurred in persons ≥15 years of age. In countries with stronger historical vaccination programs and higher country income, case patients had higher median ages.
Although most measles case patients are <15 years of age, an age shift is seen in countries with a higher income or a stronger historical vaccination program. Countries must strengthen immunization programs to achieve high vaccination coverage; some must undertake strategies to reach persons ≥15 years of age and close immunity gaps.
自疫苗问世以来,麻疹发病率和死亡率显著下降。然而,尽管取得了这一进展,麻疹在全球范围内仍呈卷土重来之势。为了了解当前的全球流行病学情况,我们分析了麻疹监测数据。
我们分析了 2013 年至 2018 年向世界卫生组织报告的麻疹病例数据。基于年龄、疫苗接种史、发病年份、世界卫生组织区域以及报告病例国家的世界银行收入状况,以及国家免疫规划历史实力的替代指标,对数据进行了单变量分析。计算了年发病率和 2013-2018 年每百万人口的平均国家发病率。
2013 年至 2018 年,共报告了 899800 例麻疹病例,其中 57%发生在未接种或接种不足疫苗的人群中,另有 30%的人疫苗接种史未知。中低收入国家占病例的 66%,23%发生在 15 岁及以上的人群中。在历史上疫苗接种方案较强、国家收入较高的国家,病例患者的中位年龄较高。
尽管大多数麻疹病例患者年龄在 15 岁以下,但在收入较高或历史上疫苗接种方案较强的国家,出现了年龄转移。各国必须加强免疫规划,以实现高疫苗覆盖率;一些国家必须采取策略,覆盖 15 岁及以上人群,并消除免疫空白。